Omnexel 400 micrograms prolonged release tablets, film-coated
Authorisation PPA1463/025/001 · IMED Healthcare Ltd.,
- Licence holder
- IMED Healthcare Ltd., (all products →)
- Active substance
- Tamsulosin hydrochloride
- Clinical trials
- 15 clinical trials →
- Dosage form
- Prolonged-release tablet
- Route of administration
- Oral use
- ATC codes
- G04CA, G04CA02
- First authorised
- 28/08/2009
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC
Tamsulosin hydrochloride: supply and approvals
27 authorised products on the HPRA list contain Tamsulosin hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 19 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 19 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 17 years (since 28 August 2009). The HPRA list does not say whether it is on sale.
Other medicines with Tamsulosin hydrochloride in Ireland
26 other products on the HPRA list contain Tamsulosin hydrochloride, from 13 licence holders; 11 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Combodart 0.5 mg/ 0.4 mg hard capsules | GlaxoSmithKline (Ireland) Limited | National authorisation (PA) | Marketed |
| Dutasteride/Tamsulosin Hydrochloride 0.5 mg/0.4 mg hard capsules | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Marketed |
| Dutasteride/Tamsulosin Rowa 0.5 mg/0.4 mg hard capsules. | Rowa Pharmaceuticals Limited, | National authorisation (PA) | Marketed |
| Dutasteride/Tamsulosin hydrochloride 0.5 mg /0.4 mg hard capsules | Viatris Limited | National authorisation (PA) | Marketed |
| Dutasteride/Tamsulosin hydrochloride Pinewood 0.5 mg/0.4 mg hard capsules | Pinewood Laboratories Ltd | National authorisation (PA) | Marketed |
| Omnexel®, 400 micrograms prolonged release tablets, film-coated | Astellas Pharma Co. Limited | National authorisation (PA) | Marketed |
| TAMSU 400 micrograms modified-release capsules, hard | Rowex Limited, | National authorisation (PA) | Marketed |
| Tamnexyl XL 400 micrograms prolonged-release tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Tamnic 400 micrograms Modified-release Capsules, hard | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Tamsulosin 400 micrograms Modified-release Capsules, Hard | Viatris Limited | National authorisation (PA) | Marketed |
| Vesomni 6 mg/0.4 mg modified-release tablets | Astellas Pharma Co. Limited | National authorisation (PA) | Marketed |
| Combodart 0.5 mg/ 0.4 mg hard capsules | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
Other substances in ATC group G04CA
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group G04CA with this product:
Dutasteride (6) · Terazosin (5) · Silodosin (4) · Alfuzosin hydrochloride (3)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
IMED Healthcare Ltd., holds 178 products on the HPRA list, with 119 different active substances; 1 of the products is marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.